ASCO GI | Jan 19-21, 2023 | San Francisco, CA
EMMA | Jan 27-28, 2023 | Vienna, Austria
ESMO GYN | Feb 23-24, 2023 | Barcelona, Spain
SGO | Mar 25-28, 2023 | Tampa, FL
HOPA | Mar 29-Apr 1, 2023 | Phoenix, AZ
NCCN | Mar 31-Apr 2, 2023 | Orlando, FL
AACR | Apr 14-19, 2023 | Orlando, FL
EMN | Apr 20-23, 2023 | Amsterdam, Netherlands
ONS | Apr 26-30, 2023 | San Antonio, TX
MPN MDS US Focus Meeting | Apr 28-29, 2023 | Phoenix, AZ
COMY | May 11-14, 2023| Paris, France
ASCO | Jun 2-6, 2023 | Chicago, IL
EHA | Jun 8-11, 2023 | Frankfurt, Germany
SOHO | Sep 6-9, 2023 | Houston, TX
IASLC (WCLC) | Sep 9-12, 2023 | Singapore
IMS | Sep 27-30, 2023 | Athens, Greece
ESGO | Sep 28-Oct 01, 2023 | Istanbul, Turkey
ESMO | Oct 20-24, 2023 | Madrid, Spain
SITC | Nov 1-5, 2023 | San Diego, CA
JADPRO | Nov 9-12, 2023 | Orlando, FL
ASH | Dec 9-12, 2023 | San Diego, CA
(niraparib)
Material Safety Data Sheets Environmental Risk Assessments Environmental Risk Assessments Important Prescribing Information Dec 2022 Important Prescribing Information Sept 2022(dostarlimab-gxly)
Material Safety Data Sheets Environmental Risk AssessmentsThe growing understanding of tumor cells’ ability to evade immune surveillance has led to advances in the field of immuno-oncology.1
Malignant cells manipulate a variety of physiological mechanisms involved in antigenicity, immune activation, T-cell priming and recruitment, and upregulation of checkpoint molecules.1 Many of these mechanisms may be impacted simultaneously to promote tumor cell survival.1 Immunotherapies harness the body’s own immune system to fight cancer by using different immunological pathways to enhance antitumor responses.1,2
GSK is exploring different clinical assets aimed at augmenting the immune response, reducing immune suppression, and modulating the tumor microenvironment.3,4
Immuno-Oncology | Phase I | Phase II | Phase III |
---|---|---|---|
|
|||
DREAMM-3: Relapsed/Refractory Multiple Myeloma alone vs Pomalidomide/Dexamethasone |
NCT04162210 | ||
DREAMM-7: Relapsed/Refractory Multiple Myeloma in Combination with Bortezomib and Dexamethasone vs Daratumumab/Bortezomib/Dexamethasone |
NCT04246047 | ||
DREAMM-9: Newly Diagnosed Multiple Myeloma in Combination with Lenalidomide, Bortezomib, and Dexamethasone |
NCT04091126 | ||
DREAMM-4: Relapsed/Refractory Multiple Myeloma in Combination With Pembrolizumab |
NCT03848845 | ||
DREAMM-5: relapsed/refractory multiple myeloma alone and in combination with GSK3174998 (OX40 agonist antibody) or GSK3359609 (ICOS agonist IgG4 antibody) |
NCT04126200 | ||
Relapsed/refractory multiple myeloma in Chinese patients |
NCT04177823 | ||
DREAMM-6: Relapsed/Refractory Multiple Myeloma in Combination With Lenalidomide Plus Dexamethasone or in Combination With Bortezomib Plus Dexamethasone |
NCT03544281 | ||
Relapsed/Refractory Multiple Myeloma in Japanese Patients |
NCT03828292 | ||
DREAMM-12: Relapsed/Refractory Multiple Myeloma in Normal or Varying Degrees of Impaired Renal Function |
NCT04398745 | ||
DREAMM-13: Relapsed/Refractory Multiple Myeloma in Normal or Varying Degrees of Impaired Hepatic Function |
NCT04398680 | ||
|
|||
RUBY: Recurrent or Primary Advanced Endometrial Cancer in Combination With Chemotherapy |
NCT03981796 | ||
GARNET: Mismatch Repair Deficient (dMMR)/Microsatellite Instability High (MSI-H) Non-Endometrial Cancer Solid Tumors, Endometrial Cancer, Ovarian Cancer, and Non-Small Cell Lung Cancer (NSCLC) |
NCT02715284 | ||
IOLite: Advanced NSCLC and Solid Tumors in Combination With Niraparib (PARP Inhibitor), Cobolimab (Anti-TIM-3 Antibody), Bevacizumab, and/or Platinum-Based Doublet Chemotherapy |
NCT03307785 | ||
|
|||
INDUCE-3: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) in Combination with Pembrolizumab |
NCT04128696 | ||
INDUCE-4: Recurrent/Metastatic HNSCC in Combination with Pembrolizumab and 5-Fluorouracil (5-FU) Platinum Chemotherapy |
NCT04428333 | ||
ENTREE-Lung: Advanced NSCLC in Combination With Docetaxel |
NCT03739710 | ||
INDUCE-2: Advanced Solid Tumors in Combination With Tremelimumab |
NCT03693612 | ||
INDUCE-1: Advanced Solid Tumors Alone and in Combination With Pembrolizumab or Chemotherapy |
NCT02723955 | ||
|
|||
AMBER: Melanoma, NSCLC, and Colorectal Cancer Alone and in Combination With Dostarlimab (Anti-PD-1 Antagonist) |
NCT02817633 | ||
|
|||
CITRINO: Advanced Solid Tumors Alone and in Combination With Dostarlimab |
NCT03250832 | ||
|
|||
Advanced Solid Tumors Alone and in Combination With Pembrolizumab |
NCT03843359 | ||
|
|||
INTR@PID BTC 055: First-line treatment in combination with gemcitabine plus cisplatin in locally advanced/metastatic biliary tract cancer (BTC) |
NCT04066491 | ||
INTR@PID BTC 047: Second-line locally advanced/metastatic BTC |
NCT03833661 | ||
INTR@PID CERVICAL 017: advanced, unresectable cervical cancer that progressed during or after platinum-containing chemotherapy. |
NCT03833661 | ||
INTR@PID UROTHELIAL 152: locally advanced/metastatic urothelial cancer that progressed or recurred after platinum-containing chemotherapy |
NCT04349280 | ||
INTR@PID LUNG 005: Unresectable Stage III NSCLC in Combination With Concurrent Chemoradiation Therapy |
NCT03840902 | ||
INTR@PID LUNG 024: stage IV NSCLC in combination with chemotherapy |
NCT03840915 | ||
INTR@PID SOLID TUMOR 001: Locally Advanced or Metastatic Solid Tumors |
NCT02517398 | ||
INTR@PID SOLID TUMOR 008: Locally Advanced or Metastatic Solid Tumors |
NCT02699515 | ||
|
|||
ENGAGE-1: Advanced Solid Tumors Alone and in Combination With Pembrolizumab |
NCT02528357 | ||
Advanced Solid Tumors in Combination With GSK3174998 (OX40 Agonist), GSK3359609 (ICOS Agonist), or Pembrolizumab |
NCT03447314 | ||
|
|||
Advanced NY-ESO-1– and/or LAGE-1a–positive solid tumors |
NCT03515551 | ||
|
|||
Advanced Solid Tumors Alone and In Combination with Dostarlimab |
NCT04446351 |
Accumulation of DNA damage and genomic instability are pervasive characteristics of human tumors and are caused by defects in DNA repair.1,2 Deficiencies in essential DNA damage repair in cancer cells may increase dependency on an alternate repair pathway for cell survival.2 Synthetically lethal therapies aim to combine pharmacologic inhibition of these alternate repair pathways with inherent defects in DNA damage repair to selectively kill tumor cells while sparing healthy tissue.2-4 GSK is investigating a clinical asset that utilizes the power of synthetically lethal interactions to fight malignant cells in a variety of cancers.
Synthetic Lethality | Phase I | Phase II | Phase III |
---|---|---|---|
|
|||
FIRST†: Ovarian Cancer maintenance in combination with or without dostarlimab and bevacizumab following first-line treatment with Platinum-Based Chemotherapy with or without dostarlimab and bevacizumab |
NCT03602859 | ||
OVARIO: Ovarian Cancer First-Line Maintenance in Combination With Bevacizumab Following Response on Front-Line Platinum-Based Chemotherapy Plus Bevacizumab |
NCT03326193 | ||
OPAL: Platinum-Resistant Ovarian Cancer Treatment in Combination With Dostarlimab and Bevacizumab |
NCT03574779 | ||
MOONSTONE: Platinum-Based Ovarian Cancer Treatment in Combination With Dostarlimab |
NCT03955471 | ||
Neoadjuvant Treatment in HER2- and BRCAmut Localized Breast Cancer |
NCT03329937 | ||
Pharmacokinetics and Safety in Patients With Advanced Solid Tumors and Normal Hepatic Function or Moderate Hepatic Impairment |
NCT03359850 | ||
Crossover Bioavailability Study of Niarparib Tablet Compared to Niraparib Capsule in Advanced Solid Tumors |
NCT03329001 |
Aberrant gene expression, regulated in large part by epigenetic mechanisms, is a hallmark of cancer.1 “Epigenetics” refers to heritable changes in gene expression that arise from changes in chromosomes without altering the DNA sequence.2 DNA methylation and posttranslational modifications of histones play key roles in regulating gene expression.1,3 Deregulation of these epigenetic mechanisms can lead to aberrant expression of oncogenes and tumor suppressors in cancer cells that can enhance proliferative signals, impair cell death, promote angiogenesis, and facilitate metastasis. GSK is investigating compounds that work by altering these epigenetic pathways.
Cancer Epigenetics | Phase I | Phase II |
---|---|---|
|
||
Relapsed/Refractory Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), and Chronic Myelomonocytic Leukemia (CMML) |
NCT03614728 | |
Solid Tumors and Non-Hodgkin's Lymphoma (NHL) |
NCT02783300 | |
|
||
Relapsed/Refractory Solid Tumors and Diffuse Large B-Cell Lymphoma (DLBCL) |
NCT03666988 |
The physiologic role of central and peripheral tolerance mechanisms is to limit unchecked immune responses that can lead to autoimmunity.1 In cancer, these mechanisms are major limitations to effective T-cell mediated antitumor immunity.1 Oncology cell therapy uses adoptive transfer of engineered T cells that may mediate antitumor effects. In adoptive cell therapy, T cells are isolated from the patient, engineered to present an enhanced TCR that recognizes a specific antigen, and then reintroduced into the patient.1,2 This innovative approach generates T cells that may be more efficient at targeting cancer cells and may overcome the barriers of tolerance mechanisms2 GSK is developing an engineered TCR T-cell clinical asset designed to target a tumor-specific antigen and eliminate malignant cells in solid tumors and hematologic malignancies.
Oncology Cell Therapy | Phase I | Phase II | Phase III |
---|---|---|---|
|
|||
IGNYTE-ESO: master protocol–advanced NY-ESO-1– and/or LAGE-1a–positive synovial sarcoma and solid tumors |
NCT03967223 | ||
Relapsed/Refractory NY-ESO-1– and/or LAGE-1a–Positive Multiple Myeloma Alone and in Combination with Pembrolizumab |
NCT03168438 | ||
Advanced Myxoid/Round Cell Liposarcoma |
NCT02992743 | ||
Advanced NY-ESO-1– and/or LAGE-1a–Positive NSCLC Alone and in Combination with Pembrolizumab |
NCT03709706 | ||
Long-Term Follow-up from Previous GSK3377794 Studies |
NCT03391778 |
December 10-13, 2022 | New Orleans, LA
November 8-12, 2022 | Boston, MA
October 27-30, 2022 | Berlin, Germany
October 27-28, 2022 | Brooklyn, NY
September 29-October 1, 2022 | New York, NY
September 28-October 1, 2022 | Houston, TX
September 28-29, 2022 | Chicago, IL
September 9-13, 2022 | Paris, France
August 25-27, 2022 | Los Angeles, CA
August 6-9, 2022 | Vienna, Austria | Virtual
June 9-12, 2022 | Vienna, Austria | Virtual
June 3-7, 2022 | Chicago, IL | Virtual
April 8-13, 2022 | New Orleans, LA
March 18-21, 2022 | Phoenix, AZ
Healthcare Disparities in Gynecological Cancers Deck
Endometrial Cancer Therapeutic Discussion Deck
Biomarkers: Defective Mismatch Repair and Microsatellite Instability in Endometrial Cancer Deck
Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors Deck
Diagnosis and Management of Immune Related Adverse Events Infographic
Get answers to your questions about GSK products. Enter your zip code to find your local Clinical Medical Liaison.